BrainStorm Cell Therapeutics, an Israeli drugmaker specializing in central nervous system disorders, says that it is expanding its R&D program to include the treatment of the effects of stroke. The first animal efficacy studies are expected to start in the fourth quarter of the year.
The Tel Aviv-based firm will apply NurOwn, its bone marrow-derived stem cell therapeutic products, to the condition, which strikes over 15 million people worldwide every year, leaving 5.5 million permanently disabled and another 6 million dead.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze